non-small cell lung cancer
Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology
Premium
The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.
Black Diamond Therapeutics IND for BDTX-1535 Cleared by FDA
The company will initiate a Phase I trial of the MasterKey inhibitor in EGFR-mutated glioblastoma multiforme and non-small cell lung cancer.
Merck's Keytruda Improves Disease-Free Survival in Allcomers in Adjuvant NSCLC Trial
In an interim analysis, the drug also improved disease-free survival in patients with high PD-L1 expression but failed to reach statistical significance.
Amgen's Lumykras Garners European Commission Conditional Approval for KRAS-Mutated Lung Cancer
Regulators relied on data from the CodeBreaK-100 trial to approve the treatment for advanced, previously treated NSCLC patients with KRAS G12C mutations.
In Brief This Week: Cullinan Oncology, Aileron Therapeutics, Sanofi, Exscientia
News items for the week of Jan. 3, 2022.